Bupropion treatment of attention-deficit hyperactivity disorder in adults.
The authors treated 19 adults with attention-deficit hyperactivity disorder with an open trial of bupropion. These patients had received maintenance stimulant medication or monoamine oxidase inhibitors for an average of 3.7 years. Fourteen of the patients experienced moderate to marked benefit from bupropion; ten of these patients chose to continue bupropion rather than their former medication. These results suggest that bupropion may be an alternative to stimulants in treating some adults with attention-deficit hyperactivity disorder.
Wender
P H
PH
Department of Psychiatry, University of Utah School of Medicine, Salt Lake City 84182.
Reimherr
F W
FW
D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D016642:Bupropion; D002986:Clinical Trials as Topic; D003913:Dextroamphetamine / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D011427:Propiophenones / Q000627:therapeutic use*
D000928:Antidepressive Agents; D008996:Monoamine Oxidase Inhibitors; D011427:Propiophenones; D016642:Bupropion; D008774:Methylphenidate; D003913:Dextroamphetamine